Recent Security Class Actions

Eiger BioPharmaceuticals Inc. Common Stock (NASDAQ: EIGR)

43 Days left to seek lead plaintiff status.

Company Name:Eiger BioPharmaceuticals Inc. Common Stock
Stock Symbol:NASDAQ: EIGR
Class Period Start:03/10/2021
Class Period End (inclusive):10/04/2022
Filing Deadline:01/09/2023

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) Defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the peginterferon lambda EUA; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the FDA was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Eiger BioPharmaceuticals Inc. Common Stock (NASDAQ: EIGR) Claim Form

Name(Required)
Address
Consent(Required)
This field is for validation purposes and should be left unchanged.